| Chitosan |
- |
MRI |
Chemotherapy (camptothecin) |
Folate |
In vivo magnet-guided MRI and treatment for Kunming mice bearing H22 tumor [18] |
| Polyvinyl alcohol/polyacrylic acid |
100-150 |
MR/fluorescence imaging |
Chemotherapy (doxorubicin and curcumin) |
Lactoferrin |
In vivo magnet-guided fluorescence imaging and treatment for BALB/c nude mice bearing RG2 glioma tumor [19] |
| Amphiphilic polymer (undefined) |
20 |
MR/fluorescence imaging |
Chemotherapy (doxorubicin) |
IGF1 peptide |
In vivo targeted MR/fluorescence imaging and treatment for nude mice bearing orthotopic pancreatic patient-derived xenograft tumor [24] |
| PLGA |
80-100 |
MR/fluorescence imaging |
Chemotherapy (tamoxifen) |
Herceptin |
In vitro test for pH-/thermal-responsive drug release and in vivo chemotherapy for MCF-7 tumor treatment [26] |
| PNIPAM copolymer |
170 |
MR/fluorescence imaging |
Chemotherapy (curcumin) |
None |
In vitro temperature sensing and temperature-responsive drug release with NIR irradiation or AMF [28] |
| PNIPAM |
370-430 |
MR/fluorescence imaging |
Chemotherapy (5-fluorouracil) |
None |
In vitro thermal-responsive drug release for 7901 cell treatment [29] |
| PEG/chitosan |
52 |
MR/fluorescence imaging |
Chemotherapy (methotrexate) |
Methotrexate (mimic folate) |
In vivo targeted MR and fluorescence imaging with protease-mediated drug release to inhibit Hela tumor growth in Sprague-Dawley rats [31] |
| Dextran |
21 |
MR/fluorescence imaging |
Chemotherapy (azademethylcolchicine) |
None |
In vivo MRI and targeted drug activation in MMP-14 expressed MMTV-PyMT tumor with low toxicity to normal tissue of FvBN mice [32] |
| Chitosan-PEG grafted PEI |
41 |
MRI |
Gene therapy (siRNA) |
Anti-GPC3 Ab |
In vivo targeted delivery of siRNA for orthotopic HCC therapy in athymic Nu/J mice [41] |
| Phospholipid-PEG |
45-50 |
MRI |
Immunotherapy (dsRNA analog); Chemotherapy {Pt(IV)} |
None |
In vitro evaluation for combined chemoimmunotherapy for cancer treatment [42] |
| PEO-b-PCL |
190 |
MRI |
PTT (Au); Chemotherapy (paclitaxel) |
None |
In vitro test of combined chemotherapy and PTT to MCF-7 and MDA-MB-231 cells [48] |
| PEI/PEG |
150 |
MRI/CT/PAI |
PTT (Au) |
Folate |
In vivo trimodal imaging and PTT treatment for Hela tumors [49] |
| PDA/PDM |
210 |
MRI/CT/PAI |
Gene therapy (plasmid DNA); PTT (Au) |
None |
In vivo trimodal imaging and PTT/genetherapy for C6 glioma tumor-bearing BALB/c nude mice [50] |
| PEG/PPy |
100 |
MRI/PAI |
PTT (PPy) |
None |
In vivo MRI/PAI and PTT treatment for BALB/c nude mice bearing 4T1 tumor [52] |
| C18PMH-PEG |
100 |
MRI |
PTT (PPy) Chemotherapy (doxorubicin) |
None |
In vivo MRI and chemotherap/PTT treatment for BALB/c nude mice bearing 4T1 tumors [53] |
| PEG |
14-18 |
MR/fluorescence imaging |
PDT (Ce6); Chemotherapy (doxorubicin) |
Red blood cell |
In vivo MR and fluorescence imaging and chemotherapy/PDT to suppress 4T1 tumor growth in BALB/c nude mice [56] |
| Phospholipid-PEG |
28-30 |
MRI |
Hyperthermia (SPION); Chemotherapy (doxorubicin) |
None |
In vitro study of combined hyperthermia and chemotherapy to Hela cells [60] |
| PEG/PPy |
153 |
MRI |
Hyperthermia (SPION); Chemotherapy (doxorubicin) |
None |
In vivo MRI and combined hyperthermia/chemotherapy to control HepG2 tumor growth in nude mice [61] |
